<?xml version="1.0" encoding="UTF-8"?>
<p id="para0024">Toxicity concerns are a major potential liability of ribonucleoside analogs as underscored, for instance, by the compromised safety profile of T-705.
 <xref rid="bib0099" ref-type="bibr">
  <sup>99</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0102" ref-type="bibr">
  <sup>102</sup>
 </xref> A primary source for adverse effects is incorporation of the ribonucleoside analogs into host RNAs by nuclear and mitochondrial RNA polymerases.
 <xref rid="bib0112" ref-type="bibr">
  <sup>112</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib0113" ref-type="bibr">
  <sup>113</sup>
 </xref> The integrity of mitochondrial transcripts is particularly at risk due to the proofreading inability of mitochondrial RNA polymerases in contrast to nuclear RNA Pol II.
 <xref rid="bib0114" ref-type="bibr">
  <sup>114</sup>
 </xref> Not surprisingly, NHC was incorporated by human mitochondrial polymerases in in vitro studies
 <xref rid="bib0115" ref-type="bibr">
  <sup>115</sup>
 </xref> and an elevated frequency of NHC-characteristic transition events was noted after prolonged exposure of primary human airway epithelium cells to the drug. However, the transition mutation frequency in ferret lung tissue was unchanged from that in controls after extended treatment of animals with 200 mg/kg daily dose and thus over 14-times the efficacious dose for influenza therapy.
 <xref rid="bib0106" ref-type="bibr">
  <sup>106</sup>
 </xref> Potential adverse effects of EIDD-2801 on embryo development are untested at present, and formal 2-species multi-dose toxicity studies will be required to establish initial human doses examined in phase 1 clinical trials.
</p>
